All Activity

“South Carolina can take an important step forward on regulating the hemp industry, protecting our families and ensuring access to these products.” By David Spang, Coastal Green Welless via South Carolina Daily Gazette In South Carolina, the hemp industry is at a crossroads. Without sensible regulation for the sale of hemp and hemp-derived products, we risk undercutting public safety, damaging industry credibility and putting South Carolina small businesses in jeopardy. Current South Carolina law does not regulate products containing hemp-derived cannabinoids, aside from limiting delta-9 THC to 0.3 percent on a dry weight basis under federal law. This gap has allowed a rapid increase in products, from gummies to vapes, with little to no oversight or guidelines. Fortunately, there is a solution. For the last several years, the South Carolina Healthy Alternatives Association has worked to develop a reasonable and responsible regulatory framework for the state’s hemp industry. As the legislative session opens in Columbia, an amendment to House Bill 3924 provides an opportunity to implement that framework. With the support of numerous legislators, we believe this amendment will make the proposal the only legislation that accomplishes the goals of our industry, law enforcement, and most importantly, protects the public. States around the country, including Georgia, Tennessee, West Virginia and Kentucky have passed bills to responsibly regulate hemp and hemp-derived products in their states. Additionally, last month’s White House order on reclassifying marijuana also gave clear direction on full-spectrum hemp, signaling further support for consumable hemp products. It’s time South Carolina joined its peers, ensuring access to these products for people who have come to rely on them, and protecting small business owners and the public from bad actors. In December, local, state and federal law enforcement conducted “Operation Ganjaprenuer,” a series of coordinated operations against criminals trafficking illegal drugs across South Carolina. Unfortunately, these actions also impacted legitimate businesses selling legal hemp products across the state. For those businesses, Attorney General Alan Wilson (R) called for exactly what is needed: a reasonably and responsibly regulated South Carolina hemp industry. That means creating a framework for responsible regulations for hemp-derived consumable products to include the following: Limiting sales to individuals 21 and over Testing requirements to ensure safe and compliant products for consumers Packaging and labeling requirements Licenses for manufacturers, distributors/wholesalers and retailers Serving size restrictions For responsible businesses trying to operate legitimately, the current patchwork of interpretations and inconsistent enforcement is unsustainable. Business owners committed to doing things the right way are forced to compete with bad actors who cut corners, mislabel products or target minors. South Carolina can take an important step forward on regulating the hemp industry, protecting our families and ensuring access to these products. If we can amend H3294 with complete regulatory guidelines and send it to Gov. Henry McMaster’s (R) desk, we will ensure South Carolina catches up to the responsible regulations of our peer states. This piece was first published by South Carolina Daily Gazette. David Spang is the founder of Coastal Green Wellness, which sells hemp products. He’s also chairman of the South Carolina Healthy Alternatives Association, a group advocating for the responsible regulation of the hemp-derived products industry. A South Carolina native, he lives in Myrtle Beach. Photo courtesy of Max Jackson. The post South Carolina Lawmakers Should Pass Hemp Legislation That Smartly Regulates Products (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

117. Ibogaine Therapy Safety & Ethics: What Responsible Care Really Looks Like A grounded conversation on ibogaine therapy safety and ethics—covering medical oversight, risks, integration, and responsible psychedelic care. Episode Summary Ibogaine is often described as a breakthrough for addiction, trauma, and PTSD—but it’s also one of the most medically complex psychedelic therapies in use today. In this episode, April Pride sits down with Tom Feegel and Talia Eisenberg, co-founders of Beond Ibogaine, to explore what ethical, medically supported ibogaine care actually requires. Together, they unpack the difference between iboga and ibogaine, why cardiac screening and clinical monitoring are non-negotiable, and how integration—not intensity—is where real change happens. Talia shares her personal recovery story, Tom explains Beond’s safety-first model, and April grounds the conversation in harm reduction, nervous system care, and responsibility. This episode will help you understand the real risks, the emerging science, and the ethical questions shaping ibogaine’s future—without hype or shortcuts. Key Takeaways Iboga and ibogaine are not the same—and that distinction matters for safety, dosing, and ethics. Ibogaine carries real cardiac risk and should never be used without medical screening and monitoring. Post-acute withdrawal can last weeks or months and is a major relapse risk without support. Whole-plant medicines vary in potency; predictability is a safety issue, not a comfort preference. Integration starts before the medicine and continues long after—it’s a way of living, not a checklist. Timestamps [00:00] Safety disclaimer, why harm reduction matters, and setting the context[01:00] Iboga vs. ibogaine: what’s the difference and why it matters[03:00] Tom’s story: trauma, recovery, and building the place that didn’t exist[07:30] Talia’s first ibogaine experience and the risks of unregulated care[09:00] What post-acute withdrawal really looks like[12:00] Spiritual seeking, Osho, and early inner guidance[14:00] “Root medicine” and why support after the experience is critical[17:00] Potency variability: mushrooms, cannabis, and iboga compared[18:00] Cardiac risk, medical screening, and ethical boundaries[23:00] PTSD, TBI, and what the emerging research suggests[27:00] Cannabis use disorder, ketamine, kratom, and modern dependency patterns[31:00] What a medically supported ibogaine program actually includes[34:00] Integration vs. activation: turning insight into lived change[38:00] How to evaluate whether ibogaine care is right for you Guests Follow Tom Feegel & Talia Eisenberg: Beond Ibogaine | https://beondibogaine.com | https://www.instagram.com/beondibogaine Additional Resources SetSet Psychedelic Cards Women in the Wild application Learn more about this episode: https://aprilpride.substack.com/p/ibogaine-therapy-safety-and-ethics Hosted by April Pride Subscribe for April’s newsletter on Substack at https://aprilpride.substack.com/subscribe or at getsetset.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Follow on IG: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠youtube.com/@getsetset⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / X: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@getsetset Get full access to SetSet with April Pride at aprilpride.substack.com/subscribeCatch the full episode here

A Florida Senate panel has advanced legislation to ban smoking or vaping marijuana in public places, a development that comes as an industry-funded campaign is seeking to place a recreational cannabis legalization initiative on the November ballot. The Senate Regulated Industries Committee on Tuesday approved the bill, which defines a public place as “a place to which the public has access, including, but not limited to, streets; sidewalks; highways; public parks; public beaches; and the common areas, both inside and outside, of schools, hospitals, government buildings, apartment buildings, office buildings, lodging establishments, restaurants, transportation facilities, and retail shops.” The measure from Sen. Joe Gruters (R), who is also chairman of the Republican National Committee, would specify that marijuana cannot be smoked or vaped in customs smoking rooms at airports. Sen. Ana Maria Rodriguez (R) presented the bill, SB 986, on Gruters’s behalf at the committee hearing. “There is currently no prohibition on smoking marijuana in public places if adult use is approved by the voters,” she said, according to Florida Politics. “By banning public smoking of marijuana, we are protecting community health and quality of life, as well as protecting certain outdoor spaces from marijuana smoke such as beaches and parks.” Rep. Alex Andrade (R) is sponsoring a similar bill to ban public cannabis smoking in the House of Representatives. The proposals are among a growing list of cannabis legislation that lawmakers are introducing for consideration next year. Here’s an overview of other pending Florida marijuana bills: A House lawmaker is sponsoring a bill to legalize recreational marijuana that also aims to break up what he calls “monopolies” in the state’s current medical cannabis program by revising the business licensing structure. Another representative’s bill would protect the parental rights of medical cannabis patients, preventing them from losing custody of their children for using their medicine in accordance with state law. Other lawmakers are sponsoring legislation to expand the state’s medical marijuana program, in part by increasing supply limits for patients and waiving registration fees for honorably discharged military veterans. The proposals would also allow doctors to recommend cannabis to any patient who has a condition for which they have been prescribed opioids. Other recently filed bills in the legislature for 2026 would more incrementally reduce medical cannabis patient registration fees for military veterans and clarify that smoking or vaping marijuana in public places is prohibited. A senator is sponsoring a bill to legalize home cultivation of marijuana for registered medical cannabis patients in the state. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, a campaign is working against the clock to collect enough signatures to again put the question of adult-use marijuana legalization to voters at the ballot. But there have been complications. Most recently, the Republican attorney general of Florida and several business and anti-marijuana groups urged the state Supreme Court to block the legalization initiative, calling it “fatally flawed” and unconstitutional. The briefs were filed days after Smart and Safe Florida filed a new lawsuit against state officials, alleging that they improperly directed the invalidation of about 71,000 signatures as a turn-in deadline approaches. In March, meanwhile, two Democratic members of Congress representing Florida asked the federal government to investigate what they described as “potentially unlawful diversion” of millions in state Medicaid funds via a group with ties to Gov. Ron DeSantis (R). The money was used to fight against the 2024 citizen ballot initiative, vehemently opposed by the governor, that would have legalized marijuana for adults. The lawmakers’ letter followed allegations that a $10 million donation from a state legal settlement was improperly made to the Hope Florida Foundation, which later sent the money to two political nonprofits, which in turn sent $8.5 million to a campaign opposing Amendment 3. The governor said last February that the newest marijuana legalization measure is in “big time trouble” with the state Supreme Court, predicting it would be blocked from going before voters this year. “There’s a lot of different perspectives on on marijuana,” DeSantis said. “It should not be in our Constitution. If you feel strongly about it, you have elections for the legislature. Go back candidates that you believe will be able to deliver what your vision is on that.” “But when you put these things in the Constitution—and I think, I mean, the way they wrote, there’s all kinds of things going on in here. I think it’s going to have big time trouble getting through the Florida Supreme Court,” he said. In 2023, the governor accurately predicted that the 2024 cannabis measure from the campaign would survive a legal challenge from the state attorney general. It’s not entirely clear why he feels this version would face a different outcome. While there’s uncertainty around how the state’s highest court will navigate the measure, a poll released last February showed overwhelming bipartisan voter support for the reform—with 67 percent of Florida voters backing legalization, including 82 percent of Democrats, 66 percent of independents and 55 percent of Republicans. Separately, Florida medical marijuana officials are actively revoking the registrations of patients and caregivers with drug-related criminal records. The policy is part of broad budget legislation signed into law last year by DeSantis. The provisions in question direct the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges. In the background, a recent poll from a Trump-affiliated research firm found that nearly 9 in 10 Florida voters say they should have the right to decide to legalize marijuana in the state. Photo courtesy of Brian Shamblen. The post Florida Lawmakers Approve Bill To Ban Public Marijuana Smoking Ahead Of Possible Legalization Vote On The Ballot appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Attorney General Pam Bondi has missed a congressionally mandated deadline to issue guidelines for easing barriers to research on Schedule I substances such as marijuana and psychedelics. Under legislation passed by lawmakers and signed into law by President Donald Trump last year, Bondi was supposed to publish interim rules setting out new processes for Schedule I research registration by January 16—but that has not occurred. “This failure to act leaves researchers, institutions and regulators without clear guidance and directly contributes to research harm—the preventable damage caused when restrictive or unclear drug policies obstruct legitimate scientific research,” Kat Murti, executive director of Students for Sensible Drug Policy (SSDP), said in a press release on Tuesday. “Research harm delays medical innovation, limits evidence-based policymaking and slows the development of potential treatments for overdose, pain, addiction and mental health conditions.” “Congress gave the attorney general a clear deadline and a clear mandate: reduce barriers to research while ensuring transparency and public input,” Murti said. “Missing this deadline is not a neutral administrative failure—it actively perpetuates research harm. When scientists are left navigating vague or contradictory rules, lifesaving research is delayed, innovation stalls and public health suffers.” While drug policy reform advocates have sounded the alarm about the main thrust of the bill, which is to permanently place analogues of the opioid fentanyl into Schedule I of the Controlled Substances Act (CSA), there are components that could help facilitate studies into drugs, including cannabis, psilocybin, MDMA and others. The Congressional Research Service (CRS) broke down the various provisions of the law—the Halt All Lethal Trafficking of Fentanyl Act (HALT Fentanyl Act)—in a report last year, including its potential impact on studies into currently controlled substances. “Section 3 of the HALT Fentanyl Act contains multiple provisions designed to streamline research with Schedule I controlled substances,” CRS said. “The section applies generally to Schedule I substances, including but not limited to [fentanyl-related substances, or FRS.]” It would do so by amending statute in a way that creates a “simplified registration process for researchers whose research” is funded by the U.S. Department of Health and Human Services (HHS) or the U.S. Department of Veterans Affairs (VA), for example. The revised registration process would also apply to entities studying Schedule I drugs under an Investigational New Drug (IND) exemption from the Food and Drug Administration (FDA). “Under the new process, the researcher may submit a notice to [the Drug Enforcement Administration] containing the controlled substance to be used in the research, the quantity of the substance to be used, demonstration that one of the above criteria is met (e.g., the grant or project number and identification of the funding agency or the IND application number), and demonstration that the researcher is allowed to do the research under the law of the state where the research will be conducted,” the CRS report said. “Researchers currently registered to conduct research with Schedule I or II controlled substances may begin their new research within 30 days of the notice to DEA,” it says. “For a researcher without a current registration, DEA must act within 45 days of receiving all required information either to register the applicant or issue an order for the applicant to show cause why registration should not be denied.” Another change under the new law makes it so DEA-registered researchers will not have to obtain a separate registration for a Schedule I drug “if the manufactured quantities are small and are produced for purposes of the research and the researcher notifies DEA of the manufacturing activities and the quantities of the substance in question.” “It allows for the creation of different forms of the substance consistent with the research and further allows dosage form development studies to be performed in order to apply to FDA for an IND exemption,” CRS said, while noting that the section “also specifies that it does not provide authority to grow marijuana.” But advocates say the streamlining of research can only occur if the attorney general follows through and issues new guidelines for implementing the law. “These provisions have the potential to reduce research harms—but only if they are implemented clearly, consistently, and in consultation with the scientific community,” Dr. Alaina Jaster, Ph.D., pharmacologist and toxicologist and Co-Chair of SSDP’s Science Policy Committee, said. “Without guidance, confusion and delay are inevitable.” Trump also issued an executive order last month directing Bondi to quickly complete the process of moving marijuana from Schedule I of the CSA to Schedule III, but that has not yet occured. The post Attorney General Misses Deadline For Rules To Make It Easier To Study Schedule I Drugs Like Marijuana And Psychedelics appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congressional leaders have released another large-scale funding bill and related reports that contain cannabis provisions. The new package would require Customs and Border Protection (CBP) to provide a briefing on seizures of marijuana products from state-legal businesses, direct a health agency to publish information about cannabinoid hyperemesis syndrome and block transportation officials from encouraging illegal drug or alcohol use in impaired driving PSAs. The appropriations deal, covering Fiscal Year 2026 spending for Defense; Homeland Security; Labor, Health and Human Services, Education; and Transportation, Housing and Urban Development, was released by leaders of the House and Senate Appropriations Committees on Tuesday. One section of the report for the Department of Homeland Security appears to be responsive to CBP seizures of cannabis products from state-licensed businesses in New Mexico: “Cannabis Seizures. -Within 120 days of the date of enactment of this Act, CBP shall provide to the Committees a briefing on cannabis seizures to include products containing cannabis or related paraphernalia that are possessed, sold, or transferred by a cannabis distributor in compliance with applicable state or tribal law and regulations.” CBP has been sued by New Mexico marijuana businesses over the seizures, and Gov. Michelle Lujan Grisham (D) has vocally pushed back on those actions. Now, it seems, congressional leaders are demanding the agency provide information about how its enforcement actions are impacting operators who are acting in accordance with state law. The report for the Department of Health and Human Services, meanwhile, directs the Centers for Disease Control and Prevention (CDC) to publish information about cannabinoid hyperemesis syndrome (CHS) in youth: “Cannabinoid Hyperemesis Syndrome in Youth.-The agreement directs CDC to publicly release a report regarding Cannabinoid Hyperemesis Syndrome in Youth within 180 days of the enactment of this Act.” CHS is a condition in which people experience nausea, vomiting and abdominal pain after consuming cannabis. Under the new report directive, CDC would have to issue a public report on the condition. The new funding bill itself contains a provision blocking the National Highway Traffic Safety Administration (NHTSA) from using any of its appropriated monies to “encourage illegal drug or alcohol use” in its public service announcement advertising campaigns: “SEC. 141. None of the funds provided in this Act may be used to encourage illegal drug or alcohol use in the National Highway Traffic Safety Administration’s impaired driving advertising campaigns.” The rider is seemingly in response to previous marketing materials that leaned into cannabis culture to deter impaired driving. Marijuana legalization opponents cheered when a similar provision was approved last year. Finally, the legislation maintains a rider that blocks the use of funds for “any activity that promotes the legalization of any drug or other substance included in schedule I” of the Controlled Substances Act. “SEC. 509. (a) None of the funds made available in this Act may be used for any activity that promotes the legalization of any drug or other substance included in schedule I of the schedules of controlled substances established under section 202 of the Controlled Substances Act except for normal and recognized executive-congressional communications. (b) The limitation in subsection (a) shall not apply when there is significant medical evidence of a therapeutic advantage to the use of such drug or other substance or that federally sponsored clinical trials are being conducted to determine therapeutic advantage.” The provision has been included in federal spending legislation since the 1990s. Rep. Alexandria Ocasio-Cortez (D-NY) in past years has attempted to get that language deleted by arguing that it impedes research on psychedelics, but her amendments have been defeated. Lawmakers have recently advanced other federal spending legislation that would continue protecting state medical cannabis programs from federal interference while excluding a provision that would have prevented the Trump administration from rescheduling cannabis. An additional funding package contains a rider that would keep blocking Washington, D.C. from legalizing recreational marijuana sales. Separately in Congress, bipartisan House and Senate lawmakers are pushing to delay enactment of a law that will federally recriminalize hemp THC products that was signed by President Donald Trump late last year. The post Congressional Leaders Push Feds To Explain Marijuana Product Seizures From State-Legal Businesses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Bipartisan senators are weighing in on the Trump administration’s marijuana rescheduling process—including how it could impact the fight to ease banking access for cannabis businesses. Sen. Cory Booker (D-NJ) told Marijuana Moment on Wednesday that it’s “too early to tell” what the implications of President Donald Trump’s executive order directing the Department of Justice to expedite the process of moving cannabis from Schedule I of the Controlled Substances Act (CSA) to Schedule III will be—saying that while there are “things that look promising” about it, he is “very concerned about where the DOJ will land.” “The ability of the Trump administration to speak out of both sides of their mouth is staggering,” he said. “So I’m just going to wait and see right now. Obviously, there’s things that look promising—to end generations of injustice. I really want to wait and see.” DOJ has so far not provided any updates or timelines on the rescheduling process since Trump issued his executive order last month, and Attorney General Pam Bondi—who has historically opposed marijuana reform—was not present at the signing ceremony. Booker added in the interview with Marijuana Moment that the administrative rescheduling move could potentially open to the door to advancing additional cannabis reforms in Congress such as the Secure and Fair Enforcement Regulation Banking Act (SAFER) Banking Act, which would make it easier for marijuana businesses to access financial services. “As a legislator, for me, that might get us an opening to some of the things that are stalled in Congress,” he said. “But ultimately that’s where I feel more comfortable, so that no matter who the president is, we have a structure that works to end the injustices and to liberate, frankly, an industry that has been severely hamstrung.” The senator, who at one point threatened to block the advancement of industry-focused banking legislation if it did not include more equity-focused provisions, said that he’s since “been able to get into SAFER some of the elements that are important to me to be able to support it.” That is likely a reference to the addition of language clarifying that the bill’s safe harbor for banks that work with cannabis businesses is extended to Community Development Financial Institutions (CDFIs) and Minority Depository Institutions (MDIs) that make commercial loans to minority-owned businesses. That said, a current version of the SAFER Banking Act has not yet been reintroduced in either the House or the Senate more than a year after the 119th Congress began. On Thursday, Sen. Bernie Moreno (R-OH), who is expected to be the lead sponsor of the legislation this session, told Marijuana Moment that marijuana banking is “stacked ranked very low” as a priority “because we just have a lot of irons in the fire right now.” Issues that take precedence include “funding the government, getting this healthcare thing done, crypto market structure,” he said. Asked whether the administrative move to reschedule cannabis takes some pressure off of lawmakers to act, he said, “I think so, probably.” Last week, two other GOP senators filed an amendment to block the Trump administration from rescheduling cannabis, but it was not considered on the floor. Meanwhile, earlier this month, the Drug Enforcement Administration (DEA) said a marijuana rescheduling appeal process “remains pending” despite Trump’s executive order. A recent Congressional Research Service (CRS) report discussed how DOJ could, in theory, reject the president’s directive or delay the process by restarting the scientific review into marijuana. The LCB contributed reporting from Washington, D.C. The post Democratic Senator ‘Very Concerned’ About How DOJ Will Handle Marijuana Rescheduling appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Excellent post. I was reviewing this blog continuously, and I am impressed! Extremely helpful information especially this page. Thank you and good luck. olxtoto Took me time to read all the comments, but I really enjoyed the article. It proved to be Very helpful to me and I am sure to all the commenters here! It’s always nice when you can not only be informed, but also entertained! editoto This is a great inspiring article.I am pretty much pleased with your good work.You put really very helpful information. Keep it up. Keep blogging. Looking to reading your next post. sengtoto I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. olxtoto Very useful post. This is my first time i visit here. I found so many interesting stuff in your blog especially its discussion. Really its great article. Keep it up. olxtoto basket168

This is my first time visit to your blog and I am very interested in the articles that you serve. Provide enough knowledge for me. Thank you for sharing useful and don't forget, keep sharing useful info: situs togel terpercaya I have read your blog it is very helpful for me. I want to say thanks to you. I have bookmark your site for future updates. situs toto Thank you very much for writing such an interesting article on this topic. This has really made me think and I hope to read more. bandar slot online Nice to be visiting your blog again, it has been months for me. Well this article that i've been waited for so long. I need this article to complete my assignment in the college, and it has same topic with your article. Thanks, great share. demo slot pg soft mahjong This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value. Im glad to have found this post as its such an interesting one! I am always on the lookout for quality posts and articles so i suppose im lucky to have found this! I hope you will be adding more in the future... prediksi toto macau situs slot gacor

IN House rejects marijuana amendment; Study: Cannabis classification not aligned with science; Op-Ed: CBD patients need more than fed hemp ban delay Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Free to read (but not free to produce)! We’re proud of our newsletter and the reporting we publish at Marijuana Moment, and we’re happy to provide it for free. But it takes a lot of work and resources to make this happen. Cole Preston of ColeMemo.com: “I support Marijuana Moment because consistent, factual reporting on drug policy is essential—especially as laws change faster than public understanding. Their work helps keep policymakers, advocates and the public grounded in what’s actually happening.” If you value Marijuana Moment, invest in our success on Patreon so we can expand our coverage and more readers can benefit: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW U.S. Department of Agriculture scientists published a study that the agency says “redefined the value of roots in industrial hemp, providing new opportunities for industrial hemp growers and opening new avenues for pediatric cancer research.” The Indiana House of Representatives rejected an amendment that would have allowed farmers to begin cultivating marijuana seed with new special use permits—which the sponsor said would help the state “get prepared” for federal cannabis rescheduling. A new scientific review concludes that “U.S. drug policy does not align with experts’ rankings of drug harms”—finding, for example, that “cannabis was rated as less harmful than its Schedule I status suggests.” Realm of Caring Executive Director Sasha Kalcheff-Korn argues in a new Marijuana Moment op-ed that for hemp farmers and patients who rely on CBD, delaying the federal recriminalization of hemp products is “just a band-aid” and that “regulatory certainty” is needed. The Missouri Division of Cannabis Regulation revised guidance to attempt to clarify whether medical marijuana patients can buy from licensed dispensaries as adult-use consumers—though purchase limit rules complicate the situation. / FEDERAL White House Office of National Drug Control Policy Director Sara Carter Bailey said officials are seeing fentanyl “laced in vapes and marijuana.” Sen. Ted Budd (R-NC) tweeted, “Rescheduling marijuana to a Schedule III substance will put more money in the pockets of marijuana companies & will have detrimental effects on the health and safety of Americans, especially our nation’s youth.” Sen. Susan Collins (R-ME) said in a press release about the Senate Judiciary Committee’s approval of President Donald Trump’s nominee for U.S. attorney for Maine that she’s concerned about “illegal Chinese marijuana grow houses” in her state. / STATES The Maine legislature’s Veterans and Legal Affairs Committee is considering a bill to legalize marijuana consumption lounges. The Ohio legislature’s Ibogaine Treatment Study Committee will meet on Wednesday. A Florida judge issued a split ruling on state officials’ decision to toss signatures for a proposed marijuana legalization ballot initiative. A spokesperson for a Massachusetts campaign seeking to roll back marijuana legalization with a proposed ballot initiative addressed accusations of fraudulent petitioning tactics. The organizer of an Arizona campaign behind a proposed ballot initiative to recriminalize recreational marijuana sales discussed the measure. Michigan regulators published a report on the hemp program. Pennsylvania’s medical cannabis program has seen a decline in patient enrollment over the past year. California regulators are launching a compliance education effort on kratom and 7-OH products ahead of enforcement actions. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Niles Township. Michigan officials are being sued over a local ban on marijuana businesses. The Boston, Massachusetts Cannabis Board will meet on Wednesday. / INTERNATIONAL Victoria, British Columbia, Canada’s police chief said he doesn’t expect to see a spike in drug arrests when the province’s decriminalization trial is concluded at the end of this month. German lawmakers are considering scaling back some proposed restrictive changes to medical cannabis policies. / SCIENCE & HEALTH A study highlighted “the potential of CBD as an adjunctive therapeutic agent for cancer treatment versus non-malignant cells.” A study found that “longer sitting times are associated with a lower likelihood of marijuana use among U.S. adults.” A study found that “acute migraine treatment with 6% THC + 11% CBD was superior to placebo at 2-h post-treatment with sustained benefits at 24 and 48 h.” / ADVOCACY, OPINION & ANALYSIS The New York Post editorial board criticized Gov. Kathy Hochul’s (D) plan to create a Center for Excellence for Cannabis Care and Health Equity. / BUSINESS Colorado retailers sold $108.2 million worth of legal marijuana products in October. / CULTURE A shuttered marijuana business co-owned by Ice-T is facing a lawsuit over allegedly unpaid bills. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post Feds tout hemp roots’ potential in kids’ cancer treatment (Newsletter: January 20, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Le code promo 1xBet gratuit: VATOUT. Découvrez comment l'utiliser lors de votre inscription pour obtenir jusqu'à 130 $ de bonus de bienvenue. 1xBet propose des promos sur les paris sportifs et les jeux tout au long de l’année. Chaque mois, des offres récompensent les joueurs actifs, avec des avantages qui varient selon la période et les événements sportifs. nouveau code promo 1xbet

This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free. togel terpercaya This article gives the light in which we can observe the reality. This is very nice one and gives indepth information. Thanks for this nice article. bandar togel Thank you a bunch for sharing this with all of us you actually realize what you are talking about! Bookmarked. Please also seek advice from my site =). We could have a hyperlink change contract between us! bandar slot Very informative post! There is a lot of information here that can help any business get started with a successful social networking campaign. slot gacor This blog is really great. The information here will surely be of some help to me. Thanks!. syair macau situs slot

est une option fiable pour garder la main sur vos identifiants. code promo 1xbet abidjan

This article highlights the impactful role of women in the cannabis industry through social media. They're building communities and dismantling stigmas. It's inspiring to see this collaboration. It's almost like watching players level up skills strategically, similar to the precision needed in Ragdoll Archers . The legal cannabis world is gaining strength thanks to these dedicated women.

I have read a few of the articles on your website now, and I really like your style of blogging. I added it to my favorites blog site list and will be checking back soon. Please check out my site as well and let me know what you think. apollo tv group

One of the biggest strengths of the Dinosaur Game is its accessibility. It requires no installation, no account, and no learning curve. Anyone with Google Chrome can play it instantly, regardless of age or gaming experience.

What truly makes Geometry Dash unique is its deep connection between gameplay and music. Every jump, fall, and movement is synchronized with energetic electronic tracks.

By removing direct defensive control, Retro Bowl emphasizes strategic decisions and offensive execution rather than overwhelming the player with complex mechanics.

“Merely hitting pause does not protect public health; thoughtful regulation does.” By Sasha Kalcheff-Korn, Realm of Caring While some policymakers are proposing to delay impending hemp restrictions by extending the 2018 Farm Bill, this is just a band-aid and might ultimately create a significant missed opportunity. An extension may temporarily allow farmers to plant this season, but it does nothing to solve the underlying problem. Kicking the can down the road only prolongs uncertainty for farmers, patients and families, plus it guarantees we will be having the same crisis conversation again next year. We create an industry that can’t plan for the future. The right solution is not just delay; it is clarity. Congress has a narrow window right now to fix the language, correct the THC threshold and clearly distinguish intoxicating products from non-intoxicating, therapeutic CBD—and it should take that opportunity while there is momentum and support to do so. Farmers do not need temporary relief; they need regulatory certainty that allows them to operate responsibly and sustainably. And most importantly, the patients and families who rely on this medicine need therapeutical tools they can depend on. Claims that we need “more research” to determine intoxicating levels of THC in CBD products ignore the substantial body of evidence that already exists. Scientific literature, clinical experience and real-world data consistently demonstrate that non-intoxicating CBD products can contain trace amounts of THC well below any level that produces intoxication. This is not theoretical, but it is observable, measurable and already understood. No organization has engaged more deeply or consistently with the community using cannabinoids than Realm of Caring. Through tens of thousands of direct, recorded interactions with patients, caregivers, clinicians and families across the country, we can confidently articulate what constitutes a non-intoxicating level of THC in commercially available CBD products that have been used responsibly for more than a decade. From our perspective, if lawmakers have the opportunity to pass a reasonable, evidence-based solution, particularly with encouragement from a supportive administration, they should take that shot. This challenge can be viewed as a gift for the industry to come together, end the hemp ambiguity and protect workers and patients. But merely hitting pause does not protect public health; thoughtful regulation does. Sasha Kalcheff-Korn is the executive director of Realm of Caring, a Colorado-based nonprofit that advocates for and connects people to cannabinoid therapy. The post Hemp Farmers And Patients Who Rely On CBD Need More Than Just A Delay In The Looming Federal Ban (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“It is largely up to individuals and dispensaries to ensure they are in compliance with the portion of this rule related to purchases.” By Rebecca Rivas, Missouri Independent Missouri cannabis regulators have changed their guidance on whether or not medical marijuana patients can purchase from licensed dispensaries as a regular consumer, following complaints over the last year that the state’s policy was an unconstitutional restriction. But the update ended up causing more confusion about what patients can or can’t do, cannabis advocates say. In the FAQ section of Missouri Department of Health and Senior Services’ website, it lists the question: As a qualifying patient over the age of 21, can I choose to purchase marijuana as a patient and also purchase marijuana as a consumer? Previously, the answer was a straight “no.” “…patient ID card holders are not allowed to purchase as a consumer in a licensed dispensary,” the department, which is Missouri’s cannabis regulatory agency, stated. The rule, regulators said, was meant to ensure that patients and consumers stay within their allowed possession limits. But on December 8, the department changed the answer to say they don’t exactly know. It now says: “State law does not explicitly address the question of whether an individual may choose to purchase marijuana as a consumer once they have been approved as a patient and assigned a purchase and possession limit according to that status.” The Independent asked DHSS if medical patients need to show their patient ID card every time they buy marijuana from a dispensary—a question the cannabis advocacy group Missouri NORML has urged the department to clarify. Lisa Cox, spokeswoman for the department, said the law is “not clear” about it, “so DHSS is not instructing patients that they must do so,” in an email to The Independent. Dan Viets, an attorney and board member for Missouri NORML, said he’s pleased the department has changed its position on that question—but less so on another issue. Viets initially interpreted the department’s update to mean that the state now agreed with NORML that medical patients may purchase the same amount of cannabis as other adult consumers. In general, medical patients are limited to a 6-ounce allotment of dried, unprocessed marijuana every 30 days. Recreational consumers are allowed to purchase up to 3 ounces every day—but they can’t possess more than 3 ounces at any one time. Cox said it is not the department’s position that “patients and consumers have the same purchase limits. These limits are different in law, and patient limits are often specific to each individual.” She said “the law is clear” that individuals may not exceed purchase limitations by combining patient and consumer purchases. For recreational consumers, the state is prohibited by law from tracking their purchases without their permission. However by law, dispensaries are required to track how much medical marijuana patients buy so they don’t exceed their limit. And dispensaries are required to report to the department if they observe an individual exceeding their purchase or possession limits, which can lead to fines or criminal charges, the department’s website states. Cox said penalties for medical patients are uncommon, and the department has never had to revoke a patient card over possession limits. While there are some extra steps involved, Viets said there are good reasons for people to maintain their patient status. “Not only because you pay less sales tax,” Viets said, “but I think more importantly, because you enjoy the constitutional protection against employment discrimination.” Andrew Mullins, executive director of the Missouri Marijuana Trade Association, sent a letter in April to leaders of the Division of Cannabis Regulation claiming the previous FAQ wording was unconstitutional. “We believe that DCR’s interpretation that a Missourian must either be an adult-use consumer or a medical patient is neither good public policy nor a constitutionally sound interpretation,” he wrote. After the FAQ was changed online, MoCann Trade celebrated the revision. “We are thankful that despite some initial confusion, it now appears that DCR agrees that medical marijuana patients can also exercise their purchasing rights as an adult use customer, so long as they abide by the possession limit,” Mullins told The Independent. He said it’s “especially significant” because Missouri has been increasing its patient count, reaching a two-year high in medical marijuana patient applications last month. “This pro-patient policy clarification,” he said, “now complies with the Missouri Constitution and addresses the concerns we previously articulated on behalf of our medical cannabis customers.” Cox said the department is prohibited from tracking consumer purchases, “so it is largely up to individuals and dispensaries to ensure they are in compliance with the portion of this rule related to purchases.” If there is a need to verify an individual’s possession limits, such as with law enforcement, “it is important that patients know the possession limits applicable to them.” The department, she added, will provide as much guidance as it can to patients and consumers on what is allowed so that they remain within their legal possession limits. This story was first published by Missouri Independent. The post Missouri Regulators Move To Clarify Medical Marijuana Patients’ Purchasing Limits appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Indiana House of Representatives defeated an amendment aimed at allowing farmers to begin growing marijuana. The amendment, from Rep. Kyle Miller (D), would have directed the state chemist and seed commissioner to issue special use permits to between three and 10 farmers for the cultivation of marijuana seed, with geographic distribution requirements. While Miller framed the proposal as a way to prepare the state for federal marijuana rescheduling under a recent order from President Donald Trump, it was defeated in a voice vote on Thursday. “While this part of the chapter is open, we should get prepared for what Donald Trump, through his executive order, has asked—to reschedule marijuana from a Schedule I to a Schedule III,” the lawmaker said. “The longer we stick our heads in the sand, we’re hurting our farmers, we’re hurting our constituents. We need to move forward on this issue.” Rep. Mike Aylesworth (R), the sponsor of the bill about state seed law, that Miller was seeking to amend, spoke against the proposed change. “The Indiana criminal code prohibits the possession of marijuana seeds that are capable of germination. This amendment seeks to allow the state seed commissioner to offer permits to farmers for an action that is currently illegal in Indiana,” he said, according to The Times of Northwest Indiana. “The amendment does not alter the criminal code and thus creates a statutory conflict.” A poll released this month shows that nearly three in five Indiana residents back legalizing cannabis for medical and recreational use. It found that 59 percent of residents are in favor of legalizing cannabis for both medical and recreational purposes. An additional 25 percent back only allowing patients to access medical marijuana, raising the total support for that reform to 84 percent. The survey was released just days after Indiana Rep. Mitch Gore (D) filed legislation that would effectively legalize the possession and cultivation of limited amounts of marijuana. It’s one of several reform options on the table so far in the legislature for this year’s session. Cannabis reform advocates have generally struggled to make inroads in the conservative legislature over recent years. That said, the state’s GOP governor said recently that Trump’s move to federally reschedule marijuana could add “a little bit of fire” to the local push for cannabis legalization in his state. Gov. Mike Braun (R) also said last year that he’s “amenable” to medical cannabis legalization. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Braun previously said that “it’s probably time” to allow access to therapeutic cannabis among patients in the state. Those comments came alongside a separate poll indicating that nearly 9 in 10 Indiana adults (87 percent) support marijuana legalization. Top Republicans in the legislature, however, have openly opposed marijuana reform. “It’s no secret that I am not for this,” Senate President Pro Tem Rodric Bray (R) said in late 2024. “I don’t have people coming to me with really compelling medical cases as to why it’s so beneficial. And any state that I’ve seen pass medical marijuana is essentially passing recreational marijuana.” House Speaker Todd Huston (R) doubted any medical benefits associated with marijuana, calling the substance “a deterrent to mental health.” He and others suggested that lawmakers supportive of the reform merely want to boost state revenue. A number of marijuana reform bills were introduced for the Indiana legislature’s 2025 session, including one—from Reps. Jim Lucas (R) and Shane Lindauer (R)—that would have legalized medical marijuana for people with “serious medical conditions as determined by their physician.” The post Indiana House Rejects Amendment To Let Farmers Begin Cultivating Marijuana Seeds appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Marijuana and other drugs are not as dangerous as laws written half a century ago say they are, according to a new scientific review. Since the passage of the Controlled Substances Act (CSA) in 1970, U.S. drug laws have been dictated by rigid categories that supposedly reflect the dangers posed by different substances—but the new study suggests that “drug policy contradicts expert assessments of drug harms” both in America and across the world. The results indicate that governments’ legal rankings for substances bear little resemblance to what experts actually know about which drugs cause the most harm—something that cannabis consumers and much of the general public have long recognized. Marijuana, for example, has been listed as a Schedule I drug in the U.S. for decades. While President Donald Trump signed an executive order directing the attorney general to expeditiously complete the process of moving cannabis to a Schedule III substance last month, that has not yet occurred. In the new paper published in the December 2025 issue of Harm Reduction Journal, a multidisciplinary panel of U.S. researchers, clinicians and people with lived experience of substance use found that federal drug policy is “poorly aligned with scientific evidence” and often contradicts expert assessments of risk. To reach their conclusions, the researchers adapted a method known as multi-criteria decision analysis. Seventeen experts evaluated 19 commonly used drugs across 18 categories of harm, ranging from overdose death and long-term health damage to family disruption, crime and economic cost. Each drug was scored and weighted to produce an overall harm ranking. The study—titled “US drug policy does not align with experts’ rankings of drug harms: a multi-criteria decision analysis”—also found that nearly all drugs were more harmful to the people who use them than to others, a result with significant policy implications. “An array of harm reduction strategies should be considered,” the authors argue, noting that punitive approaches have coincided with rising overdose deaths rather than declines in use. The findings arrive at a moment when federal and state officials are reconsidering long-standing approaches to drug regulation, sentencing and public health response. “For example, cannabis was rated as less harmful than its Schedule I status suggests.” By placing cannabis in the most restrictive legal category—while ranking fentanyl lower in Schedule II and leaving alcohol outside the federal drug scheduling system entirely—U.S. policy has created a framework that the authors say no longer reflects either scientific consensus or actual risk to the population. “Resources should be focused on health and wellness, not on incarceration,” they wrote. Taken together, the study paints a picture of a drug policy frozen in time—one that treats substances like cannabis and psilocybin as major threats while failing to adequately respond to the substances doing the greatest damage. As fentanyl deaths climb and alcohol-related harms persist, the authors suggest that aligning law with evidence is no longer just an academic concern, but a public health imperative. “Psilocybin and cannabis are associated with less harm than many other drugs and with potential medicinal benefits but people who use them remain subject to punishment in many jurisdictions.” The researchers argue that evidence-based scheduling could support a shift away from punitive enforcement and toward targeted harm reduction, expanded treatment access and public health interventions, particularly for fentanyl and alcohol. Noting that “fentanyl was deemed the most harmful drug,” they point to evidence supporting naloxone distribution, fentanyl test strips and supervised consumption sites. Calling for further examination, the authors write that the research “provides a useful starting point for future work in the U.S. that could account for additional drugs, drug benefits, vulnerable subpopulations (e.g., youth), and various methods of use and routes of ingestion.” “Collectively, this work can be used to advance scientific debate about the best ways to reduce harms to people who use drugs and to redress societal impacts at the same time.” The study comes on the heels of the Trump administration backing away from a prior federal recommendation to limit alcohol consumption to specific amounts, even as marijuana remains federally criminalized and more Americans are choosing cannabis for personal health reasons. More changes are also on the horizon. President Trump signed a bill into law last year containing provisions that would remove barriers to conducting research into the risks and benefits of marijuana, psychedelics and other Schedule I drugs. The post Marijuana’s Restrictive Federal Classification Isn’t Supported By Science, New Study Concludes appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Combinés : cumulez plusieurs sélections pour booster vos gains code promo 1xbet casino

You can be permitted to content artists, however it is not connections, in the event they are simply endorsed and additionally relating to question. iptv deutschland

Les autres offres accessibles avec le code promo 1xBet code promo 1xbet yaoundé

The "Wortendo word game" serves as a bridge between traditional word puzzles and modern digital interfaces, preserving the intellectual satisfaction of paper-based puzzles while adding the convenience and features of digital platforms. This hybrid approach respects the history of word games while leveraging technology's advantages, like instant dictionary validation and progress tracking.